Medically reviewed on July 13, 2016.
Applies to the following strengths: 14 mg; 7 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Multiple Sclerosis
7 mg or 14 mg orally once a day
Use: Treatment of patients with relapsing forms of multiple sclerosis.
Renal Dose Adjustments
No adjustment recommended.
Liver Dose Adjustments
-Mild and moderate hepatic impairment: No adjustment recommended
-Severe hepatic impairment: Contraindicated
US BOXED WARNINGS:
Hepatotoxicity: Severe liver injury including fatal liver failure has been reported in patients treated with leflunomide, which is indicated for rheumatoid arthritis. A similar risk would be expected for teriflunomide because recommended doses of teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide.
-Obtain transaminase and bilirubin levels within 6 months before initiation of treatment and monitor ALT levels at least monthly for six months.
-If drug induced liver injury is suspected, discontinue treatment and start accelerated elimination procedure.
Risk of Teratogenicity: Based on animal data, teriflunomide may cause major birth defects if used during pregnancy.
-This drug is contraindicated in pregnant women or women of childbearing potential who are not using reliable contraception.
-Pregnancy must be avoided during treatment.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available.
Administration advice: Administer with or without food.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about teriflunomide
- Teriflunomide Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- En Español
- 39 Reviews
- Drug class: selective immunosuppressants
Other brands: Aubagio